The recent decision by the DEA to reschedule cannabis to Schedule III has triggered notable volatility in the market valuations of multi-state operators (MSOs).

According to Viridian Capital Advisors' latest weekly credit report, the MSO index surged by 25% immediately after the announcement, indicating a strong initial market reaction. However, this enthusiasm quickly faded, with the index dropping by 15% the following day.

These shifts are significant as they influence the perceived financial health of these companies, judged by their market value and their ability to manage their debts.

MSOs Adjust To DEA Rescheduling

How are these shifts reflected in the financial trajectories of major MSOs? According to Viridian Capital Advisors' analysis, several MSOs are navigating different financial paths post-DEA rescheduling.

In contrast, Trulieve's (OTC:TCNNF) current yield stands at 8.7% with a 380 basis point over the curve, suggesting a potentially more balanced risk-return profile.

Meanwhile, companies like Verano (OTC:VRNOF), Cresco (OTC:CRLBF), and Curaleaf (OTC:CURLF) are trading yields in the 11-11.5% range, highlighting varying degrees of risk and investment attractiveness.

Ascend Wellness: High Yield, High Risk

Additionally, Ascend’s complex market position and diverse geographic presence pose challenges for potential acquisitions. According to Viridian, addressing its upcoming debt maturity proactively could significantly improve its financial standing and market valuation.

Photo: AI-Generated Image.